What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

Published 4th September 2018, updated 4th September 2018 · UKMi

This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

Cardiovascular system disordersDalteparinEnoxaparinHaematological disordersParenteral AdministrationQ&ATinzaparinTravel Medicine

Attachments

Varinder Rai

Regional Medicines Information Manager, London Medicines Information Service

  • Rate this page

  • 5/5 (1)

  • Didn’t find what you were looking for?

    If you need to know more you can ask one of our experts for help.

    Ask a question